IP Cases — 2004
39 decisions across all jurisdictions
Page 2 of 2 · 39 total
Novartis Ag v.Adarsh Pharma And Anr.
The plaintiff, Novartis Ag, sought to confirm an ex parte injunction granted under Exclusive Marketing Rights (EMR) for its product, Beta Crystalline form of Imatinib Mesylate. The defendant challenged this injunction, arguing that no patent was ever filed in India and the EMR was vague. The court ultimately confirmed the injunction, finding prima facie materials favored the plaintiffs.
Usv Limited v.Systopic Laboratories Limited
Usv Limited filed a suit for passing off against Systopic Laboratories Limited, alleging that the latter was deceptively using similar trade marks ('PIO-15'/'PIO-30') for medicinal preparations. The court examined issues of jurisdiction and whether the defendant's use caused confusion or deception.
Jolen Inc. v.Mr. Shobanlal Jain, Hindustan Rimmer
The Madras High Court reversed a lower court's decision that had dismissed an interim injunction and revoked the plaintiff's leave to institute a lawsuit. Jolen Inc., alleging infringement of its trademark 'JOLEN' and copyright in its distinctive packaging for crme bleach, successfully argued that sufficient cause of action existed based on advertisements and retail sales in India. Consequently, the court reinstated the interim injunction protecting both the copyright and passing off claims, ensuring the suit could proceed expeditiously.
Brihan Maharashtra Sugar Syndicate v.Meher Distilleries Pvt. Ltd.
The appellant challenged a trial court judgment that granted permanent injunctions in favor of the respondents regarding the alleged infringement of their copyrighted artistic label, 'PRINCE SANTRA', by using similar labels like 'No. 1 TANGO SANTRA'. The Bombay High Court heard an application for interim stay of the decree.
Glaxo Smithkline Consumer Healthcare v.Anchor Health And Beautycare Private
The plaintiffs sought an ad-interim injunction against the defendant for infringing their registered toothbrush design (No. 170554). The defendant argued that the design was not novel, was obvious imitation of existing designs, and that the plaintiffs had concealed material facts regarding prior litigation and earlier public domain designs to obtain the injunction.
Intas Laboratories Pvt. Ltd. And Anr. v.Novaritis A.G., Schwarzwaldallee,
The dispute concerned the validity of an Exclusive Marketing Right (EMR) granted to Novaritis for the anti-cancer drug, Beta-Crystalline form of Imatinib Mesylate. Intas Laboratories challenged this EMR, arguing it created a monopoly and harmed public interest due to high pricing. The Madras High Court confirmed the interim injunction but mandated that the plaintiffs supply the drug freely to eligible patients.
Milmet Oftho Industries & Ors. v.Allergan Inc.
The Supreme Court addressed a passing off dispute concerning the pharmaceutical mark 'OCUFLOX' between an Indian company and a multinational corporation. While acknowledging the global nature of medicine and the potential harm from confusion, the court emphasized that the ultimate test remains who was first in the market. The judgment directed the trial court to continue the injunction while expediting the suit for final determination based on evidence regarding prior use.
Rajapalayam Industrial And Commercial v.P. Iya Nadar Charitable Trust
The petitioner sought expunction (rectification) of the registered trade marks 'CAMEL' (Nos. 109120 and 439372), arguing that their registration in favour of the respondent charitable trust violated Section 6(2) of the Act, and that the mark had suffered dilution due to widespread use by family members. The respondent defended its right to maintain the mark.
Sun Pharmaceutical Industries Limited v.Wyeth Holdings Corporation And Anr.
The Bombay High Court dismissed the appeal filed by Sun Pharmaceutical Industries Limited against an interim order favoring Wyeth Holdings Corporation. The core dispute involved alleged infringement and passing off, where Wyeth held the registered trademark 'Pacitane' for anti-spasmodic preparations, and Sun used 'Parkitane'. The court found that due to the identical field of activity, common composition (Trihexylphenidyl), and high likelihood of consumer confusion, the appellants' use was fraudulent. Consequently, the court upheld the protective order granted to Wyeth.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.